ABPI Code Reporting
Roche strives to maintain high standards in ethical promotion of its medicines and is fully committed to the appropriate use of medicines and protecting the safety of patients.
Roche is also fully committed to, and accountable for, working within The Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice.
The ABPI is the trade association for the pharmaceutical industry in the UK.
The Code of Practice for the Pharmaceutical Industry 2011 regulates the advertising of medicines for prescription to health professionals and administrative staff and also covers information about prescription only medicines made available to the general public.
The operation of the Code is a demonstration of the industry’s commitment to transparency, as is the requirement to declare pharmaceutical company involvement in activities and materials involving the general public.
It is the Prescription Medicines Code of Practice Authority (PMCPA) which is responsible for administering The Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice for the Pharmaceutical Industry at arm’s length from the ABPI.
The pharmaceutical industry recognises that transparency is an important means of building and maintaining confidence.
As a result the Code of Practice for the Pharmaceutical Industry 2011 requires all companies to disclose: summary details and results of non-interventional studies, details of the monetary value of certain support to patient organisations and details of any so called Joint Working initiatives between a pharmaceutical company and the NHS.